X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-18 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $10.78 | -7,246 | 109,885 | -6% | -$78,112 | ||||||
2024-11-18 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $10.78 | -5,207 | 87,045 | -6% | -$56,131 | ||||||
2024-08-16 | REPL | Hill Emily Luisa | CFO | S - Sale | $10.18 | -8,938 | 101,057 | -8% | -$90,989 | ||||||
2024-06-07 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $7.50 | -15,881 | 117,131 | -12% | -$119,108 | ||||||
2024-05-16 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $6.47 | -2,218 | 92,252 | -2% | -$14,350 | ||||||
2024-05-16 | REPL | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $6.47 | -2,298 | 38,238 | -6% | -$14,868 | ||||||
2024-05-16 | REPL | Love Colin | COO | S - Sale | $6.47 | -17,615 | 777,345 | -2% | -$113,969 | ||||||
2024-05-16 | REPL | Astley-Sparke Philip | Exec COB | S - Sale | $6.47 | -37,928 | 1,487,350 | -2% | -$245,394 | ||||||
2024-05-16 | REPL | Coffin Robert | Dir | S - Sale | $6.47 | -11,464 | 1,821,872 | -1% | -$74,172 | ||||||
2024-05-16 | REPL | Patel Sushil | CEO | S - Sale | $6.47 | -20,194 | 212,014 | -9% | -$130,655 | ||||||
2024-05-16 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $6.47 | -6,367 | 133,012 | -5% | -$41,194 | ||||||
2023-11-16 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $10.92 | -7,313 | 112,714 | -6% | -$79,858 | ||||||
2023-11-16 | REPL | Sarchi Christopher | Chief Commercial Officer | S - Sale | $10.92 | -5,255 | 72,245 | -7% | -$57,385 | ||||||
| DM | 2023-09-11 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.01 | -5,658 | 263,436 | -2% | -$113,214 | |||||
| D | 2023-08-22 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.01 | -18,600 | 263,436 | -7% | -$372,186 | |||||
| D | 2023-08-11 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $20.00 | -1,400 | 263,436 | -1% | -$28,000 | |||||
| D | 2023-07-10 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $21.58 | -20,000 | 263,436 | -7% | -$431,541 | |||||
2023-06-13 | REPL | Lewis Tanya | Chief Dev. Op. Officer | S - Sale | $24.06 | -12,860 | 135,293 | -9% | -$309,395 | ||||||
2023-06-13 | REPL | Patel Sushil | Chief Strategy Officer | S - Sale | $24.05 | -5,698 | 148,873 | -4% | -$137,008 | ||||||
2023-05-16 | REPL | Patel Sushil | Chief Strategy Officer | S - Sale | $18.05 | -15,575 | 154,571 | -9% | -$281,129 | ||||||
2023-05-16 | REPL | Coffin Robert | Pres, Chief R, D Officer | S - Sale | $18.05 | -7,861 | 1,833,336 | 0% | -$141,891 | ||||||
2023-05-16 | REPL | Lewis Tanya | Chief Dev. Op. Officer | S - Sale | $18.05 | -12,207 | 148,153 | -8% | -$220,336 | ||||||
2023-05-16 | REPL | Love Colin | COO | S - Sale | $18.05 | -10,775 | 794,960 | -1% | -$194,489 | ||||||
2023-05-16 | REPL | Franchi Jean M. | CFO | S - Sale | $18.05 | -11,351 | 128,748 | -8% | -$204,886 | ||||||
2023-05-16 | REPL | Xynos Konstantinos | Chief Medical Officer | S - Sale | $18.05 | -771 | 120,027 | -1% | -$13,917 | ||||||
2023-05-16 | REPL | Esposito Pamela | Chief Business Officer | S - Sale | $18.05 | -5,966 | 263,436 | -2% | -$107,686 | ||||||
2023-05-16 | REPL | Astley-Sparke Philip | CEO | S - Sale | $18.05 | -17,902 | 1,525,278 | -1% | -$323,131 | ||||||
| D | 2022-12-09 | REPL | Esposito Pamela | Chief Business Officer | S - Sale+OE | $25.03 | -15,000 | 229,402 | -6% | -$375,450 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |